{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:25:13Z","timestamp":1785209113007,"version":"3.55.0"},"reference-count":80,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>As the prevalence of heart failure is increasing globally, left ventricular assist devices (LVADs) have become essential therapeutic options in managing advanced heart failure. This review explores the development of LVAD technology, with a focus on the shift from pulsatile to continuous-flow devices, particularly the HeartMate 3, the most advanced generation of LVADs. The evolution in design has significantly enhanced patient survival and quality of life. However, hemocompatibility-related adverse events (HRAEs)\u2014such as pump thrombosis, ischemic and hemorrhagic strokes, and gastrointestinal bleeding\u2014remain major clinical challenges. Striking the delicate balance between preventing thromboembolic events and minimizing hemorrhagic risks remains critical in LVAD patient management. Current therapeutic strategies typically involve long-term anticoagulation with vitamin K antagonists and antiplatelet therapy, though optimal management must be individualized based on patient-specific factors and device characteristics. Emerging alternatives, including low-dose anticoagulation, direct oral anticoagulants such as apixaban, and aspirin-free regimens, offer promising potential to reduce adverse outcomes. This review also highlights the role of innovative mechanical designs in minimizing shear stress and alternative treatments in preventing complications like gastrointestinal bleeding. Despite these advancements, personalized treatment strategies are critical, as no single therapeutic regimen fits all LVAD recipients. Ongoing research into both device technology and pharmacological therapies is essential to further reduce HRAEs and improve long-term outcomes for LVAD patients.<\/jats:p>","DOI":"10.1055\/a-2487-6365","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T23:30:31Z","timestamp":1740007831000},"page":"080-088","source":"Crossref","is-referenced-by-count":4,"title":["Antithrombotic Treatment for Left Ventricular Assist Devices: One Does Not Fit All"],"prefix":"10.1055","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0399-3223","authenticated-orcid":false,"given":"Emmanuelle","family":"Scala","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, Cardiothoracic and Vascular Anaesthesia, Lausanne University Hospital (CHUV), Lausanne, Switzerland"},{"name":"Faculty of Biology and Medicine, University of Lausanne (UNIL), Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-6010","authenticated-orcid":false,"given":"Alexandra","family":"Othenin-Girard","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, Cardiothoracic and Vascular Anaesthesia, Lausanne University Hospital (CHUV), Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41569-024-01046-6","article-title":"Global epidemiology of heart failure","volume":"21","author":"M S Khan","year":"2024","journal-title":"Nat Rev Cardiol"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/ejhf.2143","article-title":"The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019","volume":"23","author":"P M Seferovi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"20","key":"ref3","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1136\/heartjnl-2023-322459","article-title":"Body mass index and survival in people with heart failure","volume":"109","author":"N R Jones","year":"2023","journal-title":"Heart"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/ejhf.1594","article-title":"Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis","volume":"21","author":"N R Jones","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.athoracsur.2023.11.004","article-title":"The Society of Thoracic Surgeons Intermacs 2023 Annual Report: focus on magnetically levitated devices","volume":"117","author":"U P Jorde","year":"2024","journal-title":"Ann Thorac Surg"},{"issue":"08","key":"ref6","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/eurheartj\/ehad658","article-title":"Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry","volume":"45","author":"J D Schmitto","year":"2024","journal-title":"Eur Heart J"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/ejhf.2526","article-title":"Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF-VAD registry","volume":"24","author":"N Jakus","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.2022.16197","article-title":"Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial","volume":"328","author":"M R Mehra","year":"2022","journal-title":"JAMA"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1002\/ehf2.14444","article-title":"Survival after HeartMate 3 left ventricular assist device implantation: real-world data from Europe","volume":"10","author":"L Numan","year":"2023","journal-title":"ESC Heart Fail"},{"issue":"21","key":"ref10","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1161\/CIRCULATIONAHA.117.028303","article-title":"Hemocompatibility-related outcomes in the MOMENTUM 3 trial at 6 months: a randomized controlled study of a fully magnetically levitated pump in advanced heart failure","volume":"135","author":"N Uriel","year":"2017","journal-title":"Circulation"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.healun.2017.05.008","article-title":"Bleeding and thrombosis associated with ventricular assist device therapy","volume":"36","author":"P Shah","year":"2017","journal-title":"J Heart Lung Transplant"},{"issue":"09","key":"ref12","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jchf.2024.04.013","article-title":"Evaluation of the hemocompatibility of the direct oral anticoagulant apixaban in left ventricular assist devices: the DOAC LVAD study","volume":"12","author":"P Shah","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13054-016-1328-z","article-title":"Mechanical circulatory assist devices: a primer for critical care and emergency physicians","volume":"20","author":"A Sen","year":"2016","journal-title":"Crit Care"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/pcad.2000.7194","article-title":"History of mechanical circulatory support","volume":"43","author":"D N Helman","year":"2000","journal-title":"Prog Cardiovasc Dis"},{"issue":"07","key":"ref15","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3390\/jcm11072022","article-title":"The history of durable left ventricular assist devices and comparison of outcomes: HeartWare, HeartMate II, HeartMate 3, and the future of mechanical circulatory support","volume":"11","author":"C Berardi","year":"2022","journal-title":"J Clin Med"},{"issue":"21","key":"ref16","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1056\/NEJM199811193392107","article-title":"Implantable left ventricular assist devices","volume":"339","author":"D J Goldstein","year":"1998","journal-title":"N Engl J Med"},{"issue":"20","key":"ref17","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMoa012175","article-title":"Long-term use of a left ventricular assist device for end-stage heart failure","volume":"345","author":"E A Rose","year":"2001","journal-title":"N Engl J Med"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.athoracsur.2006.04.057","article-title":"Improved mechanical reliability of the HeartMate XVE left ventricular assist system","volume":"82","author":"F D Pagani","year":"2006","journal-title":"Ann Thorac Surg"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1527-5299.2005.04540.x","article-title":"Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study","volume":"11","author":"J W Long","year":"2005","journal-title":"Congest Heart Fail"},{"issue":"23","key":"ref20","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa0909938","article-title":"Advanced heart failure treated with continuous-flow left ventricular assist device","volume":"361","author":"M S Slaughter","year":"2009","journal-title":"N Engl J Med"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.athoracsur.2020.12.038","article-title":"The Society of Thoracic Surgeons Intermacs 2020 Annual Report","volume":"111","author":"E J Molina","year":"2021","journal-title":"Ann Thorac Surg"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jtcvs.2007.12.077","article-title":"Low thromboembolic risk for patients with the Heartmate II left ventricular assist device","volume":"136","author":"R John","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"05","key":"ref23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa1602954","article-title":"Intrapericardial left ventricular assist device for advanced heart failure","volume":"376","author":"J G Rogers","year":"2017","journal-title":"N Engl J Med"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jama.2021.11386","article-title":"FDA: stop using Medtronic's Heartware ventricular assist device","volume":"326","author":"B M Kuehn","year":"2021","journal-title":"JAMA"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/MAT.0000000000000388","article-title":"Design rationale and preclinical evaluation of the HeartMate 3 left ventricular assist system for hemocompatibility","volume":"62","author":"K Bourque","year":"2016","journal-title":"ASAIO J"},{"issue":"17","key":"ref26","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa1900486","article-title":"A fully magnetically levitated left ventricular assist device - final report","volume":"380","author":"M R Mehra","year":"2019","journal-title":"N Engl J Med"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3390\/biomedicines11030757","article-title":"Vascular function in continuous flow LVADs: implications for clinical practice","volume":"11","author":"F Khalil","year":"2023","journal-title":"Biomedicines"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/0003319720946977","article-title":"Endothelial function in patients with continuous-flow left ventricular assist devices","volume":"72","author":"P Poredos","year":"2021","journal-title":"Angiology"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.jtcvs.2013.08.043","article-title":"Insights into the mechanism(s) of von Willebrand factor degradation during mechanical circulatory support","volume":"147","author":"C R Bartoli","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.thromres.2015.11.002","article-title":"Acquired von Willebrand factor deficiency caused by LVAD is ADAMTS-13 and platelet dependent","volume":"137","author":"P Jilma-Stohlawetz","year":"2016","journal-title":"Thromb Res"},{"issue":"06","key":"ref31","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/j.jvca.2012.07.014","article-title":"Cerebral blood flow autoregulation is preserved after continuous-flow left ventricular assist device implantation","volume":"26","author":"M Ono","year":"2012","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"12","key":"ref32","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.healun.2014.08.013","article-title":"Effect of pulsatile and nonpulsatile flow on cerebral perfusion in patients with left ventricular assist devices","volume":"33","author":"W K Cornwell III","year":"2014","journal-title":"J Heart Lung Transplant"},{"issue":"03","key":"ref33","first-page":"218","article-title":"The potential adverse effects of haemolysis","volume":"15","author":"F Rapido","year":"2017","journal-title":"Blood Transfus"},{"issue":"07","key":"ref34","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.healun.2022.12.004","article-title":"The 2023 International Society for heart and lung transplantation guidelines for mechanical circulatory support: a 10-year update","volume":"42","author":"D Saeed","year":"2023","journal-title":"J Heart Lung Transplant"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1313385","article-title":"Unexpected abrupt increase in left ventricular assist device thrombosis","volume":"370","author":"R C Starling","year":"2014","journal-title":"N Engl J Med"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2016.10.001","article-title":"PREVENtion of HeartMate II pump thrombosis through clinical management: the PREVENT multi-center study","volume":"36","author":"S Maltais","year":"2017","journal-title":"J Heart Lung Transplant"},{"issue":"24","key":"ref37","doi-asserted-by":"crossref","first-page":"e027251","DOI":"10.1161\/JAHA.122.027251","article-title":"Left ventricular assist devices: a primer for the general cardiologist","volume":"11","author":"S P Chaudhry","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"08","key":"ref38","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.healun.2024.04.065","article-title":"An ISHLT consensus statement on strategies to prevent and manage hemocompatibility related adverse events in patients with a durable, continuous-flow ventricular assist device","volume":"43","author":"I B Hollis","year":"2024","journal-title":"J Heart Lung Transplant"},{"issue":"06","key":"ref39","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.healun.2019.02.009","article-title":"Prothrombotic activity of cytokine-activated endothelial cells and shear-activated platelets in the setting of ventricular assist device support","volume":"38","author":"A Apostoli","year":"2019","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"ref40","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.healun.2019.04.008","article-title":"Log files analysis and evaluation of circadian patterns for the early diagnosis of pump thrombosis with a centrifugal continuous-flow left ventricular assist device","volume":"38","author":"F Consolo","year":"2019","journal-title":"J Heart Lung Transplant"},{"issue":"09","key":"ref41","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/MAT.0000000000001654","article-title":"Improved detection of thromboembolic complications in left ventricular assist device by novel accelerometer-based analysis","volume":"68","author":"I Schalit","year":"2022","journal-title":"ASAIO J"},{"issue":"08","key":"ref42","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/CIRCRESAHA.117.310848","article-title":"Continuous-flow LVAD support causes a distinct form of intestinal angiodysplasia","volume":"121","author":"J Kang","year":"2017","journal-title":"Circ Res"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/aor.14432","article-title":"Gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices: a comprehensive review","volume":"47","author":"G Del Rio-Pertuz","year":"2023","journal-title":"Artif Organs"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.healun.2017.06.001","article-title":"Tumor necrosis factor-\u03b1 levels and non-surgical bleeding in continuous-flow left ventricular assist devices","volume":"37","author":"C E Tabit","year":"2018","journal-title":"J Heart Lung Transplant"},{"issue":"02","key":"ref45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jchf.2013.10.008","article-title":"Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device","volume":"2","author":"A L Meyer","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"03","key":"ref46","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jacbts.2021.12.005","article-title":"Hyperadhesive von Willebrand factor promotes extracellular vesicle-induced angiogenesis: implication for LVAD-induced bleeding","volume":"7","author":"M Yang","year":"2022","journal-title":"JACC Basic Transl Sci"},{"issue":"15","key":"ref47","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jacc.2010.05.016","article-title":"Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation","volume":"56","author":"N Uriel","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1178556","DOI":"10.3389\/fcvm.2023.1178556","article-title":"Left ventricular assist devices promote changes in the expression levels of platelet microRNAs","volume":"10","author":"M Lombardi","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"04","key":"ref49","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.athoracsur.2016.06.112","article-title":"Left ventricular assist device design reduces von Willebrand factor degradation: a comparative study between the HeartMate II and the EVAHEART left ventricular assist system","volume":"103","author":"C R Bartoli","year":"2017","journal-title":"Ann Thorac Surg"},{"issue":"06","key":"ref50","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.healun.2014.02.015","article-title":"Post-approval study of a highly pulsed, low-shear-rate, continuous-flow, left ventricular assist device, EVAHEART: a Japanese multicenter study using J-MACS","volume":"33","author":"S Saito","year":"2014","journal-title":"J Heart Lung Transplant"},{"issue":"01","key":"ref51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.healun.2022.10.011","article-title":"COMPETENCE Trial: the EVAHEART 2 continuous flow left ventricular assist device","volume":"42","author":"S R Allen","year":"2023","journal-title":"J Heart Lung Transplant"},{"issue":"11","key":"ref52","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/03913988221112684","article-title":"Impact of digoxin utilization on clinical outcomes following left ventricular assist device implantation","volume":"45","author":"M A Abbasi","year":"2022","journal-title":"Int J Artif Organs"},{"issue":"08","key":"ref53","doi-asserted-by":"crossref","first-page":"e004899","DOI":"10.1161\/CIRCHEARTFAILURE.118.004899","article-title":"Digoxin is associated with a decreased incidence of angiodysplasia-related gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices","volume":"11","author":"S Vukelic","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"07","key":"ref54","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.healun.2021.03.005","article-title":"Association between digoxin use and gastrointestinal bleeding in contemporary continuous flow left ventricular assist device support","volume":"40","author":"A El Rafei","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhlto.2023.100037","article-title":"Intravenous administration of umbilical cord lining stem cells in left ventricular assist device recipients: results of the uSTOP LVAD BLEED pilot study","author":"M M Ahmed","year":"2024","journal-title":"JHLT Open"},{"key":"ref56","first-page":"100142","article-title":"Intravenous administration of umbilical cord lining stem cells in left ventricular assist device recipient: Rationale and design of the uSTOP LVAD BLEED pilot study","volume":"16","author":"M M Ahmed","year":"2022","journal-title":"Am Heart J Plus"},{"issue":"06","key":"ref57","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3390\/medicina59061169","article-title":"Isolated prolongation of activated partial thromboplastin time: not just bleeding risk!","volume":"59","author":"R C Santoro","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"01","key":"ref58","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ahj.2015.03.017","article-title":"Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBIT-AF registry","volume":"170","author":"S D Pokorney","year":"2015","journal-title":"Am Heart J"},{"issue":"07","key":"ref59","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/aor.13116","article-title":"Meta-analysis of time in therapeutic range in continuous-flow left ventricular assist device patients receiving warfarin","volume":"42","author":"B K Martinez","year":"2018","journal-title":"Artif Organs"},{"issue":"01","key":"ref60","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/MAT.0000000000001572","article-title":"Time in therapeutic range significantly impacts survival and adverse events in destination therapy patients","volume":"68","author":"G P Macaluso","year":"2022","journal-title":"ASAIO J"},{"issue":"05","key":"ref61","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.healun.2018.03.002","article-title":"Evaluation of low-intensity anti-coagulation with a fully magnetically levitated centrifugal-flow circulatory pump-the MAGENTUM 1 study","volume":"37","author":"I Netuka","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12959-017-0137-1","article-title":"Perioperative management of patients on direct oral anticoagulants","volume":"15","author":"V Dubois","year":"2017","journal-title":"Thromb J"},{"issue":"05","key":"ref63","doi-asserted-by":"crossref","first-page":"e003709","DOI":"10.1161\/CIRCHEARTFAILURE.116.003709","article-title":"Increased thromboembolic events with dabigatran compared with vitamin K antagonism in left ventricular assist device patients: a randomized controlled pilot trial","volume":"10","author":"M Andreas","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"13","key":"ref64","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"J W Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"ref65","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"C B Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"08","key":"ref66","doi-asserted-by":"crossref","first-page":"e2120064","DOI":"10.1001\/jamanetworkopen.2021.20064","article-title":"Oral anticoagulants for nonvalvular atrial fibrillation in patients with high risk of gastrointestinal bleeding","volume":"4","author":"G YH Lip","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"07","key":"ref67","first-page":"e007231","article-title":"Ex vivo assessment of different oral anticoagulant regimens on pump thrombosis in a HeartWare ventricular assist device","volume":"14","author":"S D Rao","year":"2021","journal-title":"Circ Heart Fail"},{"issue":"13","key":"ref68","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1161\/CIRCULATIONAHA.118.035612","article-title":"Non-vitamin K antagonist oral anticoagulants for mechanical heart valves: Is the door still open?","volume":"138","author":"A Aimo","year":"2018","journal-title":"Circulation"},{"issue":"06","key":"ref69","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1161\/CIRCULATIONAHA.124.069726","article-title":"A prospective randomized trial of direct oral anticoagulant therapy with a fully magnetically levitated LVAD: the DOT-HM3 study","volume":"150","author":"I Netuka","year":"2024","journal-title":"Circulation"},{"issue":"04","key":"ref70","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/ehf2.14782","article-title":"Apixaban in bridge to transplant and destination LVAD - rationale and study design: the ApixiVAD trial","volume":"11","author":"B Schnegg","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"22","key":"ref71","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1001\/jama.2023.23204","article-title":"Aspirin and hemocompatibility events with a left ventricular assist device in advanced heart failure: the ARIES-HM3 randomized clinical trial","volume":"330","author":"M R Mehra","year":"2023","journal-title":"JAMA"},{"issue":"05","key":"ref72","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/MAT.0000000000000535","article-title":"Assessment of bleeding and thrombosis based on aspirin responsiveness after continuous-flow left ventricular assist device placement","volume":"63","author":"C K Floroff","year":"2017","journal-title":"ASAIO J"},{"issue":"06","key":"ref73","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.healun.2020.03.001","article-title":"Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: an analysis from the MOMENTUM 3 study","volume":"39","author":"O Saeed","year":"2020","journal-title":"J Heart Lung Transplant"},{"issue":"11","key":"ref74","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cardfail.2024.07.024","article-title":"Antithrombotic strategies with left ventricular assist devices","volume":"30","author":"M Cikes","year":"2024","journal-title":"J Card Fail"},{"issue":"04","key":"ref75","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MAT.0000000000001064","article-title":"Influence of different antithrombotic regimens on platelet-mediated thrombin generation in patients with left ventricular assist devices","volume":"66","author":"F Consolo","year":"2020","journal-title":"ASAIO J"},{"issue":"01","key":"ref76","doi-asserted-by":"crossref","first-page":"ezab474","DOI":"10.1093\/ejcts\/ezab474","article-title":"Bleeding in patients with continuous-flow left ventricular assist devices: acquired von Willebrand disease or antithrombotics?","volume":"62","author":"F Consolo","year":"2022","journal-title":"Eur J Cardiothorac Surg"},{"issue":"06","key":"ref77","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/ejhf.1468","article-title":"Do we need aspirin in HeartMate 3 patients?","volume":"21","author":"F Consolo","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"06","key":"ref78","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MAT.0000000000000859","article-title":"Discontinuation of aspirin in Heartmate 3 left ventricular assist device","volume":"65","author":"H S Lim","year":"2019","journal-title":"ASAIO J"},{"issue":"11","key":"ref79","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.jchf.2024.05.018","article-title":"Dynamic risk estimation of adverse events in ambulatory LVAD patients: a MOMENTUM 3 analysis","volume":"12","author":"P Shah","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"01","key":"ref80","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1097\/MAT.0000000000001794","article-title":"New antithrombotic strategies to improve outcomes with the HeartMate 3","volume":"69","author":"F Consolo","year":"2023","journal-title":"ASAIO J"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2487-6365.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T23:32:45Z","timestamp":1740007965000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2487-6365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":80,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,2,19]]},"published-print":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2487-6365","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}